Recent advances in understanding the mechanisms of PM2.5-mediated neurodegenerative diseases

Xiaozheng Zhu1, Xintong Ji2, Yikai Shou3

  • 1School of Medicine, Hangzhou Normal University, China.

Toxicology Letters
|May 4, 2020
PubMed

Insights

Fine particulate matter (PM2.5) exposure is linked to neurodegenerative diseases. Research indicates PM2.5 may cause neuroinflammation, oxidative stress, and neuronal damage, contributing to cognitive decline.

Area of Science:

  • Environmental Health
  • Neuroscience
  • Toxicology

Background:

  • Particulate matter (PM2.5) is primarily linked to respiratory and cardiovascular issues.
  • Emerging evidence suggests a connection between PM2.5 exposure and neurodegenerative diseases.
  • The precise mechanisms of PM2.5-induced neurotoxicity remain largely unknown.

Purpose of the Study:

  • To consolidate evidence linking PM2.5 exposure to the development of neurodegenerative disorders.
  • To elucidate the potential pathways through which PM2.5 affects the nervous system.

Main Methods:

  • Review of epidemiological studies.
  • Analysis of findings from animal experiments.
  • Examination of results from ex vivo cell culture experiments.

Main Results:

  • PM2.5 exposure is associated with increased neuroinflammation.
  • Evidence indicates PM2.5 contributes to oxidative stress and mitochondrial dysfunction.
  • Studies show PM2.5 exposure can induce neuronal apoptosis and synaptic damage.

Conclusions:

  • PM2.5 exposure is a significant risk factor for neurodegenerative diseases.
  • The findings highlight PM2.5's role in neuroinflammation, oxidative stress, and neuronal cell death.
  • Further research is warranted to fully understand and mitigate PM2.5's neurological impact.

Related Concept Videos

Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.5K
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.6K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
687